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The goal of our studies was to learn about the mech-
anism of fibronectin degradation in chronic ulcers. 
We found that the appearance of fibronectin frag-
ments in chronic ulcer wound fluid correlated with 
elevated levels of elastase and cleavage of the pro-
teinase inhibitors a2-macroglobulin (a2-M) and 0'1-
proteinase inhibitor (a1-PI) . Some wound fluid sam-
ples retained the capacity to degrade fibronectin ill 
vitro . Degradation of fibronectin by these samples was 
blocked by specific inhibitors of neutrophil elastase 
but not by inhibitors of metalloproteinases. Addition 
F ibl"Onectin degradation products have been reported in wound fluid from chronic skin ulcers (Wysocki and Grinnell, 1990; Grinnell e/ ai, 1992; Palolahti e/ ai, 1993). Although the enzyme(s) responsible for fi-bronectin degradation has yet to be identified, elevated 
levels of several proteinases- gelatinases, caseinolytic enzymes, 
and plasminogen activator (Wysocki et ai, 1993; Stacey et ai, 1993; 
Bullen et ai , 1995)-have been detected in these ulcers. Wound 
fluid samples obtained after acute burn injury also occasionally 
contain fibrone ctin fragments, which were shown to be produced 
by human ne utrophil elastase (Grinnell and Zhu , 1994) . 
Since chronic wound fluid can inhibit cell adhesion (Grinnell et 
ai, 1992) and cell growth (Belmett and Schultz, 1993 ; BucaJo et ai, 
1993), it seem s likely that persistent expression of high levels of 
unregul atcd proteinases in the wound cnvironment would contrib-
ute to the chronic condition of these wounds. Studies on other 
chronic inflammatory conditions also have demonstrated elevated 
p roteinase activity-for example, in blister fluid of patients with 
b ullous skin diseases (Oikarinen cf ai , 1983, 1993; J ensen et ai, 1988; 
La uharanta e/ ai, 1989) and in synovial fluid from patients with 
several types of arthritis (Al-Haik c/ ai, 1984; Cawston et ai, 1989; 
Partsch e/ ai, 1994) . 
Identifying th e proteinase (s) responsible for fibronectin degrada-
tion in chronic skin ulcers and learning more about factors that 
contribute to loss of regulation and persistence of en zym e activity 
are important problems not only for understanding wound patho-
gen esis , but also for developing therapeutic approaches to treating 
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of human neutrophil elastase to mastectomy fluid. an 
acute wound fluid. resulted in formation of a1-PI and 
a2-M complexes and cleavage products resembling 
those observed in chronic wound fluid. Moreover. 
degradation of fibronectin and processing of matrix 
metalloproteinase MMP- 9 occurred under these con-
ditions. Taken together. our findings suggest that 
elevated levels of neutrophil elastase are responsible 
for fibronectin degradation in the chrome wound 
environnlent. Key words: velllts stasis Idcerlproteillase.~ . 
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chronic wounds. For instance, efficacy of treatment of corneal 
ulcers with fibronectin eyedrops (Nishida el ai, 1983) was enhanced 
by adding the enzyme inhibitor aprotinin to the eyedrops (Salonen 
el ai, 1987) to control elevated levels of plasmin found in the ulcers 
(Berman e( ai, 1983 ; Salonen e/. ai, 1987). In the case of chronic skin 
ulcers , e levated levels of prote inases in the wound environment 
have the potential to inte rfere with therapeutic procedures ran ging 
from growth f.1ctor application to skin grafting. 
In the current studies , we exa mined fibron ectin degradation and 
proteinase levels in wound fluid sampled long itudinally from three 
patients with venous stasis ulcers. The results of our studies suggest 
that elastase is responsible for degradation of fibronectin in chronic 
ulcers. Moreover, addition of human neutrophil elas tase to mastec-
tomy fluid , an acute wound fluid , resulted in changes in c:d-
proteinase inhibitor, a2-macroglobulin, fibron ectin , and gelatinases 
that resembled those observed in ulcer wound fluid . 
EXPERIMENTAL DESIGN 
W ouod Fluid and Plasma This research project was approved 
by the University Institutional Review Board. Infonned consen t 
was obtained fo r all procedures. Most eJ.:periments were carned O llt 
with chronic wound fluid samples obtained at - 1-wk intervals over 
a l-mo period from three patients with venus stasis ulcers. Table I 
describes the patients and their ulcers. Each fluid collection period 
lasted for 4 h. During this time, wound fluid accumulated beneath 
a transparent polyurethane occlusive dressing (Tegaderm; 3M, St. 
Paul , MN) . Wound fluid was harvested using a sterile tuberculin 
syringe equipped with a 20-gauge stainless steel needle, with care 
being taken to avoid iI~ury to the underlyin g granulation tissue. On 
the second visit, blood samples were obtained by venipuncture with 
a 21-gauge stainless steel needle attached to a blood collection 
device (Vacutainer; Becton Dickinson, Rutherford, NJ) containing 
ethylenediamine tetraacetic acid (EDTA) anticoagulant. The eJ.:per-
iment described in Fig 5b was carried out using a sample of chronic 
wound fluid. " WFA, " described previously (Grinnell c/ ai, 1992). 
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Table I. Patient Profiles 
Age Number of Wound Size at 
Patient (y) Sex Samples" First Visit (cm) 
1 76 F 2" 5.5 X 3.0 
2 66 F 4' 7.0 X 5.0 
3 39 M 4 5 .0 X 5.5 
" Samples were coll ected at the patients ' weekly visits to the wOllnd hCOllin g cl inic. 
II T here were three visjL~. but the wound did not produ ce. sufri cic ll t fluid to collect 
'Iftcr tllC seco nd visit. 
C Pseudomonas detected at the third .. md fourth visits based on odo r and nppcarance 
of green-yellow drilinngc. 
Wound fluid samples were centrifuged at 13,500 rpm (Beckman 
]2-21M, 20 rotor) for 1.5 min at 22°C. Supernatants were frozen in 
liquid N 2 and stored at - 70°C until use . To prepare plasma from 
blood samples, ceUs were removed by centri fugation (1 ,800g for 15 
min at 22°C foIlowed by 22,000g for 30 min at 4°C). The 
supernatants were frozen in liquid N 2 and stored at - 70°C until 
use. Protein concentrations were determined by the Lowry method 
(1.951) . 
Acute wound fluid (mastectomy fluid) was obtained fi'om inpa-
tients following their mastectomy operations. T he flui.d was har-
vested from fluid collection devices (HemoVac and ConstaVac) in 
sterile test tubes beginning 24 h after surgery. Fluid coll ection 
periods lasted about 4 h. 
SDS-PAGE and Immunoblotting Sodium dodecyl sul fate-
polyacrylamide gel electrophoresis (SDS-PA GE), immulloblotting, 
and cell blotting were carried out as described pre viously (Wysocki 
et (/1, 1993; Grinnell and Zhu , 1994). Briefly, samples for SDS-
PAGE (Laemmli, 1970) were dissolved in redu cing sample buffer 
(62.5 mM Tris, 2'V" SDS, 10% glycerol, 0.01 "!., bromoph enol blue, 
pH 6.8, 5% mercaptoethan ol) unl ess indica ted otherwise and 
subjected to electrophoresis on 7.5% acrylamide mini-gels (Bio-
Rad Mini-Protean apparatus) at 22°C and 200 V for 45 min. 
Bio-Rad high-molecular mass standards were used for m arkers . 
For il11.munoblotting, polypeptides separated by SDS-PAGE were 
transferred to nitrocellul ose paper (Schl eicher and Schu ell , Keene, 
NH) by electrophores is at 22°C for 1 h at 100 V or at 22°C for 16 
h at 34 V . T he transferred proteins were in cubated with rabbit 
anti-fibronectin, rabbit anti-al -proteinase inhibitor, or rabbi t anti-
a2-macroglobul.in fo r 2 h at 22°C follow ed by in cubation with 
alkaline phosphatase-conjugated goat anti-rabbit IgG (Bio-Rad , 
.Richmond, CA) for 1 b at 22°C. Visualization was accomplished 
using the Bio-Rad alkalin e phosphatase conjugate substra te kit 
according to the manufacturer' s instructions. 
Fibronectin Degradation C hronic wound fluid (1-30 f.Lg) in 
10-20 f.LI Dulbecco's phosphate-buffered sa line (150 mM NaCl, 3 
mM KCI, 1 mM CaCI2 , 0.5 111M MgC I2' 1 111M KH2PO." 6 111M 
N a2HPO,,, pH 7 .2) was incubated with 0.5 f.Lg fibronectin for 2 h 
at 37"C. T he reactions w ere terminated by the addition of SDS-
sample buffer, and the samples were subjected to SDS-PAGE and 
iml11ul1oblotting with anti-fibronectin . Other de tails are in Materials 
below . 
Elastase Activity Elastase activity in w o und fluid was deter-
mined as described previously (Grinnell and Zhu, 1994) . C hroni c 
wound fluid samples (30 f.Lg) or human neutrophil elastase (10-50 
ng) were incubated 1 h at 22 °C in 1ml ofO.t M H epes buffe r, pH 
7.5, containing 0 .5 M NaCI, 10% dimethylsulfoxide, and 1 .0 mM 
elastase su bstra te (m ethoxys u ccin y I-a la-a I a-pro-v a I-p-n i trioa nil id e, 
methanol adduct). Substrate degradation resulted in an increase in 
optical density, which was determined by m easuring OD. II , (Beck-
man D U-40 spectrophotometer) . 
Gelatin Zymography Gelatinases were identified by zymogra-
phy (Herron et (/1, 1986) using 7.5'YrI <lcrylamide gels containing 
0 .1 % gelatin (bloom 225, Sigma C hemical Co., St. Louis, MO) , as 
described previously (Wysocki cl (/1, 1993; Grinnell and Zhu, 1994) . 
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Figure 1. F ibroncctin dcgradation pattcrns in chronic ulcer wound 
fluid arc unique to diffcrcnt paticnts. Samples (3 0 J.lg/ l:Jnc) of chronic 
wound fluid and plasma (P) fro m the patients indicated wcre subj ected to 
SOS-PAGE and analyzed by imrl1unoblotting with anti-fibroncctill. F, 
fibronc ctin st;lndard (0. 5 J.lg) . Other dctail s arc in /It/a teri(/ /s nil/I Methods. 
Areas of proteinase activ ity appeared as clear zoncs against a dark 
blue background . This me thod detects l11 e talloproteinases even if 
they arc sti ll in the proenzyme form (Herroll et ai , 1986). 
Type IV Collagenase Assay C hronic wound fluid samples (200 
f.Lg) or collagenase (0.1-10 ng) were incubated for 4 h at 37°C ill 
collagenase rea ction buiter, 0.25 ml of 0.05 M T ris-HC I, pH 7.6, 
co ntainin g 0.2 M NaCI, 5 mM CaCI2 , and 3 ILl of ' I-I_typ e IV 
human collagen (0.02 f.LC il f.L1). At the end of the incubations, the 
reactions w ere stopped by adding 20 ILl bov in e serum albumin 
(1 mg/ml) (Fracti on V, IC N Biomed. lnc., Irvine, CA) and 100 (11 
of 1 0% trichloroacetic acid/0 .5% t;ll1n ic acid. After 30 min at 4°C, 
the sampl es were centrifuged 15 min at 10,000 rpm (Beckman 
Mi cro fuge 11). Aliqu ots of the supernatants were mixed with 10 1111 
of Budget-Solve (RPI Corp., Mount Prospect, [L) and radioactivity 
was determined using a Beckman LS6000 SC li quid scintillation 
counter. 
Materials Human plasma fibro nectin was o btained from the 
New York Blood Center. Human typ e IV collagen, N-[pripionate-
2-33 H]-propionylated (1.075 mC i/mg) was obtained from NEN 
Research Products (Boston , MA) . Aminoethylbenzenesulfo-
nylfluoride (AEBSF), aprotinin, human neutrophil elastase (20 
units/mg), and elastase subst rate (#454454) were purchased from 
Calbiochel11 Co. (LaJoUa, CA). Gelatin (bloom 225), collagenase 
(Type I) , rabbit anti-a1-proteinase inhibitor, and rabbit anti-a2-
macroglobulin were purchased fi~om Sigma. The elastase inhibitor ICI 
200,355 was a gift ['·om IC I Amcl;cas Inc .. and the elastase inhibitor 
MOL 27,367 was a gift ["om M31·ion Men·el.l Dow Research Inst. 
Rabbit anti-fibronectin antibodies were prepared in our laboratol) '. 
R ES ULTS 
Fibronectin Degradation Patterns in Chronic Ulcer Wound 
Fluid Are Unique to Different Patients FibrolJectin profiles 
of plasma and ulcer wound fluid samp les from the patients sununa-
rized in Table I we re analyzed by immul1oblotting. Figure 1 
shows that fibron ectin was intact in ulcer wo und fluid sampl es fI'ol11 
Patient '1, extensively degraded in wound fluid samples (i'om Patient 
2, and intact to partia ll y degraded in sampl es fi 'om Patient 3. T hese 
results suggested that th e pattern of fihron ectin degradati on was 
unique to each pati en t and persisted over the period durin g which 
samples were coll ected. Fibronectin also was inta ct in plasma 
sampl es fr0111 all three patients, indica ting that any degradation 
occurred locally not sys tcmicall y. 
VOL. 106. N O. 2 FEI3RUA R Y 1996 
0.4 ,-------------------------------------------, 
0.3 
E 
~ 
0 
"<I' 0 .2 
-' 
<1l 
Q 
0 
0 .1 
O . O ~~~--~~~N~--~~LAN~~~~~"<I'~----D-LL~N~~~~JLL~l-~ 
HNE I I I I I I I I I 
(20 n g ) N N N N ~ M ~J ~ 
- -- P a t ient Woun d Flu id Sample 
Figurc 2. Elastase activity Illeasured with a peptidc substrate 
correlates with nbroncctin dcgradation profiles. Samples (30 Jlg) of 
chronic wound fluid from the patients indic;\t(!d or human neutrophil 
elastase w ere incubated 'with e lastase substrate. Substrate d egradation \vas 
de termined by mcasuru lg OO"ltI. Data shown arc averages from duplicate 
determinations. and duplicates vaned less than 2'%. O ther deta ils arc in 
Materinls nlld iVlet/w r/s. 
Elastase Activity Measured with a Peptide Substrate Corre-
lates with Fibronectin Degradation Profiles Figure 2 sho ws 
the levels of ela stase in the chronic wound fluid samples measured 
with an e lasta se-specific peptide substrate. E lastase ac tivity w as 
e le vated in all the wound fluid samples from Patien t 2 and those of 
Patient 3 th at contained degraded fibron ectin. On the other hand, 
li t tle de tectable elasta se activity was found in wound fluid samples 
fro m Pa tients 1 and 3 tha t contain ed mostly intact fibron ecti.l1 . 
Comparison o f Figs 1 and 2 indica tes a cl ose corre lation between 
me presence of e las tase activity and the appearan ce o f flbron ectin 
fragm ents in w o und fluid. 
Chronic Ulcer Wound Fluid Contains High Levels of 
MMP-9 Figure 3 shows the gelatinase profiles o f the chro nic 
wound fluid and plasma sampl es de termined by gelatin zymogra-
phy. All the ulcer fluid s contained high levels o f several gelatinase s. 
Consistent with pre vious findings (Wysocki et Ill , 1993; BlLll en c/ Ill , 
1995) , matrix lll c talloprote inase-9 (MMP-9) and its 135- and 
220-kDa complcxes accounted for most o f the zymographic activ-
ity. A mix ture o f proen zym e and processed (nsterisks) enzym e forms 
were evide nt (see also Fig 9B). MMP-2 (proenzyme and processed 
fo~m s) also w as observed . O ccurre ncc of fibro nectin fra gm ents in 
220 KOa -
*-
135 KOa-
proMMP-9 -
*-
proMMP-2 -
* -
--45 KOa-
#1 
P 2 P 
#2 #3 
234 P 234 
Figure 3. Chronic ulcer wound flnid contains high levels ofMMP-9 
and other gclatinases. Samples (5 ILg/lanc) of chronic wound fluid and 
plasma (P) from the patients described in Table I were subjected to gelatin 
zyrnograph y. O ther details are in M nlerinls nlld Methods. 
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Figure 4. III "itl'o degradation of fibronectin by chronic wound 
fluid. Fibronectin (F) (0 .5 ILg) was mixed with samples (30 ILg) of chronic 
wound fluid or plasma (P) from the patients indicated. After 2 h at 37°C, the 
reactions wcrc subjected to SOS-PAGE and immunoblotting wi th anti-
fibronectin . F, fibronectin standard (0.5 ILg) . O ther details are in MllIed nls 
nlld Methods. 
the wound fluid samples appeared to correlate with processed 
MMP-9 rather than to tal gelatinase levels. 
[n Samples 2-3 and 2-4 (i. e ., Patient 2, weeks 3 and 4) , a 
- 45-kDa gelatinase was de tec ted. T his p atient had a Pseudo m onas 
in fection on the days that these samples w ere collected , raising the 
possibiHty that the - 45-kDa activity was related to the infec ti on . 
III Vit/'o Degradation of Fibronectin by Chronic Ulcer 
Wound Fluid A ppearance of e las tase activity m easured w ith 
peptide substrates does not m ean that the en zym e wi ll be active 
against physio logical substra tes (i .e ., pro te ins) , since prote inases can 
cleave peptide substrates even w hen th ey are compl exed with 
a2-macrog lobulul (Laurell and J eppsson, 1975; P etersen, 1993), 
the broad specificity plasm a prote inase inhibi to r . Similarly, e levated 
gelatinase levels in zymographic an alys is does not m ean that th e 
enzym e w ilJ be active ill lI itro si.nce zym ographs can de tect proen-
zym es species and some processed enzym e-inhibitor complexes 
(Herro n ct "I, 1986). 
T o learn m o re abo ut the ulcer wound fluid enzym e (s) resp onsi-
bl e for fibronectin degradatio n, ill "itm mix.ing experimen ts w ere 
carried out in which fresh fibron ectin was incubated w ith u lcer 
w o und fluid. T his assay is primarily useful w ith WOll11d fluid sampl es 
whose endogen ous fibron ectin h as alrcady been fragm ented ill "illo 
since it is difficult to distinguish added from endogen o us fib ronectin 
except for the appearan ce of novel fragments. Figure 4 compared 
with Fig 1 sho w s that some of the w ound fluid samples w hose 
endogen ous fi bronectin had been fragm ented ill II illo also were able 
to degrade fibron ectin added ill II itro (i.e ., Samples 2- 1. 2- 4, and 
3-3) . On dle other hand , several o ther samples with endogen o us 
fibronectin fi'agm ents contained only low leve ls of ill IIit,.o fi bronec-
tin degradin g ac tivi ty (i .e., Samples 2-2, 2-3, and 3- 1) . As expected , 
no fibron ectin-degradil1g activ ity was o bserved w ith chronic 
wound fluid samples that con tained in tac t fibro nectin (i .e., Samples 
1-1 , 1-2 , 3- 2, and 3- 4). 
Elastase Inhibitors Block ill Vitl'o Fibronectin Degrada tion 
by Chronic Ulcer Wound Fluid To help iden tifY the en zym e 
in chronic wound fluid respo nsible fo r ill "itm degra dation , in hibi tor 
studies w ere carried o ut. Figure Sa shows that additio n of the 
specific n eutrophil e las tase inhibi tors IC I 200,355 (Fig 5a , T) 
(Willi am s e( Ill , 1991) or MDL 27,367 (Fig Sa , 111) (M ehdi ct aI, 
1990) , as w ell as the gen eral serine prote inase inhibi tor AEBSF (Fig 
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Figure 5. Elastase inhibitors block ill "il,'o degradation offlbronec-
tin degradation by chronic ulcer wound fluid . a) Chronic wound fluid 
(Patient 2-1 ) at the concentrations indicated was prcincubated for 10 min at 
37°C with 11 0 inhibitor (-) or with IC I (1) (10 /LM), MOL (M) (20 /LM), 
AEllSF (A) (5 mM), or EDTA (E) (10 mM), as indicated. Subsequently , 
f,bronectin (0.5 /Lg) was added to the incubations. After 2 It at 3TC, the 
reactions were subjectcd to SOS-PAG E and immunoblotting with anti -
fibronectin. F, fibronectin standard (0.5 /Lg). Other detai ls arc in Materials 
ami Melhods. b) Chronk wound fluid type A (WFA) (5 /Lg) (Grinncll el ai, 
1992) was preincubated with proteinase inhibitors including aprotinin (Ap) 
(17 /Lg/ml). Other details arc the same as in Pallcl a. 
5a, A), blocked the ability of ulcer wound fluid # 2-1 to degrade 
fibronectin. The m etalloproteinase inhibitor EDT A (Fig 5a, E), on 
the other hand , had no effec t compared with contro ls lacking 
inhibitor (Fig 5a, -). Similar experiments were carried with a 
sample of chronic ulcer wound fluid fi'om our previo us study 
(Grinnell et a/, 1992), which had been designated type A based on 
the presence of fibronectin fi·agments. Consistent with the .findings 
in Fig 5a , Fig 5b shows that ;/1 /J;/m degradation of fibron ectin by 
chronic wound fluid (Fig 5b, WFA) was blocked by AEBSF (Fig 
5b, A) or specific n eutrophil elastase inhibitors (Fig 5/J, 1,111), but 
not by EDT A (Fig 5/" E) or by the plasmin inhibi tor aprotinin (Fig 
5b, Ap). These results, along with the corre la tion between e lastase 
activity and fibronectin immunoblotting profiles (above), impJj-
ca ted wound fluid elas tase in fibronectin degradation . 
111 Vitro Degradation of Type IV Collagen by Chronic Ulcer 
Wound Fluid As an additional control, experiments were car-
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Figure 6. III vUro degradation of t-ype IV collagen by chronic ulcer 
fluid . Samples (200 /Lg) of Patient 2 chroll ic wound fluid as illdicated were 
preincubated ill co llagenase reaction bufFer for 10 min "t 3rC with AEBSF 
(A) (8 111M) or EOTA (E) (10 111M) as iJld ic"ted. Subseq uently, ' H-type IV 
coHagen was added to the incubations, which wen: "Howed to continue for 
an addi tional 4 hr . At the end of the incubations, tlw reactions were 
terminated by additioll of trichloroacetic acid and processed as described in 
Materia ls allli Mell",ds. 
ried out in which chronic wound fluid was in cubated with 3H-type 
lV collagen to determine if ill IIilro gelatinase a<;tivity was present. 
Figure 6 shows resul ts ll sing ulcer wound fluid samples from 
Patie nt 2. Degradation of collagen was highest in Samples 2-1 and 
2-3. Add iti on of EDT A blocked coHa gen-degrading enzyme activ-
ity, whereas addi tion of AEBSF had no eWect. T herefore, the 
inhibi tor specifi city for ill v;lm 3H-type IV coHagen degrada tion was 
opposite to that observed for ill I/;Im fibronectin degradation . 
Chronic Ulcer Wound Fluid Contains Cleavage Peptides of 
a2-Macroglobulin and aI-Proteinase Inhibitor T he pres-
ence of active proteinases in chronic ulcer wound fluid suggested 
that the natural proteina se inhibito rs had been destroyed or inacti-
vated. Pla sma a2-macroglo bulin (a2-M) inhibits both elastase and 
ge latinases (La ureH <lndJeppsson, 1975; Petersen, 1993; Baumstark, 
1970; N agase el a/ , 1994), and a l-prote inase inhibitor (at -PI) 
(originally called a I -a ntitrypsi n) inhibits e lastase (Laurell and 
J eppsson , 1975; Potempa cl a/, 1994) . Therefore, experimen ts were 
carried out to determin e if these two enzyme inhibitors were 
present in ulcer wound fluid . 
Figure 7 shows the iml11unoblotting patte rn of a2-M in patient 
plasma and ulcer wound fluid sampl es. Intact a2-M migrates in 
SDS-PAGE as ISO-kDa subunits, whereas a2-M clea ved at a single 
site in the bait region results in - 85-kDa cleavage peptides 
(Petersen , 1993). In tact a2-M was detected in plasma and all ulcer 
wound fluid samples. T he levels of cleavage peptides (Fig 7 , CP) of 
a2-M appeared highest in ulcer wound fluid from Patient 2, 
intermediate in wound fluid fi'om Patient 3, and lowest in wound 
fluid from Patient 1 and plasma from all of the patients. 
Figure 8 shows the immunoblotting pattern of al -Pl. lntact 
a I-PI was observed at 54 kDa in all plasma samples and in ulcer 
wound flu id from Patient 1 and Patient 3, Samples 2 and 4. 
C leavage of al -Pl (Fig 8, CP) in ulcer wound fluid resulted in a 
band at 45 kDa that migra ted slightly Ulster than cd -PI in plasma. 
This was parti cularly evident in ulcer wound fluid samples fr0111 
Patient 2 and Patient 3, Samples 1 and 3. A lso, an SDS-stable 
a I-PI-enzyme com plex (Fig 8, C) (Potempa cl a/, 1994) at 66 kDa 
was observed in the ulcer wound Buid samples. Taken together, the 
results in Figs 7 and 8 indicate that, in ul cer wound fluid £i'0111 
Patient 2 and Patient 3 (Samples 1 and 3), both c~2-M and cd -PI had 
undergone significant cleavage. T hese also were the samples that 
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F igure 7. Chronic ulcer wound fluid contains modified a2-n,acro-
globulin. Samples (6 j.Lg) of chro nic wouud fluid and plasma (P) f.·0111 the 
patients indicated were subjected to SDS-PAGE and il11muno blotting with 
anti- a2-macroglo bulin . Lalle S, 0.5 ILg a2-macroglo bulin standard . Other 
details are in M arerials ami M ethods. 
contained . fibr~nectin fragmen ts and had the greatest capa city to 
degrade fibron ectin ;/1 IJ;tro. 
Elastase Treatment of Mastectomy Fluid Produces a Phe-
notype That Resembles Chronic Ulcer Wound Fluid The 
above . findings suggested th at persistent release of neutroplul 
elastase in the wound environment, which exceeded the neutral-
ization capacity o f a2-M and a i-PI, resulted in local degradation o f 
fibronectin. As shown below, thjs reaction could be modeled i/1 
IJ itro by adding human neutroplul elastase to mastectom y fluid. 
Mastectomy fluid is an acute wound flu id that contains elevated 
levels of proMMP-9 but no processed metalloproteinases or fi -
bronectin fragments (Wysocki el Ill , 1993). 
Figure 9 shows the fibron ectin (Fig 9A) and gelatin ase (Fig 9B) 
profiles of mas tectom y fluid in cubated with in creasing concentra-
tions of human ne utrophil elastase. [n the absence of added elastase, 
fib ronectin w as intact and elevated levels of MMP-9 and its 
complexes were evident. T reatm ent of mastectomy fluid with 0.05 
ILg/ ILl elastase resulted in slight degradation of fibronec tin but no 
c-
a1-PI -
CP-
#1 #2 #3 
P12P1234P1234S 
-200 
-116 
-97 
-66 
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Figure 8 . Chronic ulcer wound fluid contains modified ai-protein-
ase inhibitor. Sampks (2 ILg) of chronic wound Auid and plasma (P) fi'ol11 
t be patients indicated were subjected to SDS-PAGE and immunoblotting 
with anti-a1-proteinase inhihito r. La lle S, 0.125 ILg a1 -pro teinasc inhibitor 
standard . Other dctail s arc in Mill crials allti Meth"ds . 
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Figure 9. Elastase treat",ent of ",astecto",y fluid results in gelati-
nase processi.ng and fibronectill degradation. Samples (75 ILg) of 
mastectomy fluid were incubated fo r 4 h at 37°C with human lleutrophil 
elastase (HNE) at th c concentrations indicated. At the end o f the incuba-
tions, the reaction mixtures were subjected to SDS-PAGE and imrnunob-
lotting w ith anti-fibronectin antibodies (A) or gelatin zymograp hy (B). 
Other detail s arc in Nia terials alld Meth"ds. 
change in the gelatinase profile. With 0.1 ILg/ ILl elastase, fibronec-
tin was completely degraded; whereas MMP-9 appeared to be 
cleaved from the proenzym e to the processed enzym e form . 
The resu lts in Fig 9 might have occurred if e lastase activated 
some other m etalloproteinase in m astectom y fluid such as strome-
lysin, which could then activate MMP-9 (Ogata et nl, 1992). In 
addition, activated MMP- 9 or another m e talloproteinase might 
have been responsible, at least in part, for degradation of fibronec-
tin. To tes t thcse possibili ties, elastase was incubated with mastec-
tomy fluid in the presence of 10 mM EDT A to block m etallopro-
teinase ac tivi ty. T he pattem of fibron ectin degradation was similar 
in the presence or absence ofEDTA. Also, with EDTA present, 
elastase treatment of mastectomy fluid resulted in MMP-9 degra-
dation rather than processing at the lower elastase concentrations 
(da ta not shown) . T hese findings were consistent wi th the idea that 
elastase was responsible for all three activities observed in Fig 9 
(i.e., fibronectin degradation, MMP processing, and MMP degra-
dation). 
Figure 10 shows analogous experiments in which the al-PI (Fig 
lOA) and a2-M (Fig lOB) profiles were determined. In the absence 
of added elastase, a l-PI was intact (54 kDa). Also, a2-M was 
mostly intac t (1 80 kDa). After m astectomy fluid samples were 
incubated with 0 .05 ILg/ml elastase, the 66-kDa aI -PI- elastase 
complex (Fig 10, C) was evident. At the same time, there was a 
marked increase in a2-M cleavage peptides (Fig 10, CP) and 
decrease i.n intact a2-M. Increasing the elastase concentration to 
0. 1 iLg/ iLl resulted in complete cleavage of al -P[ to the 4S-kDa 
cleavage fragment (CP) and degrada tion of a2-M into a series of 
fi'agments smaIJer than the cleavage peptides. Similar experimen ts 
with plasmin in place of elastase resulted in production of 8S-kDa 
a2-M cleavage products but not the 66-kDa a 1-PI complex o r the 
4S-kDa aI -PI cl eavage peptide (data not shown) although al -PT 
was degraded . 
DISC USSION 
Our studies show that appearance of fibronectin fi:agments in 
chrOluc ulce r wound fluid correlated w ith elevated levels of elastase 
and cleavage of the elastase inhibitors a2-macroglobulin and 
aI -proteinase inhibitor. Some wound fluid samples retained the 
capacity to degrade fibronectin ;11 ,, ;11'0, and degratlation of fibronec-
tin by these samples was blocked by specifi c i.nhibitors ofneutroplu.1 
elastase. M oreover, addition of human neutrophil elastase to mas-
tectomy fluid resulted in formation o f a i -PI and a2-M complexes 
and cleavage products resembling those observed in chronic wound 
fluid . Taken together, these findings suggest that elevated levels of 
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Figure 10. Elastase treatlDent of lDastectomy fluid results in for-
mation of at-proteinase inhibitor and a2-macroglobulin cleavage 
peptide. and complexes. Samples (75 JLg) of mastectomy fluid were 
incubated for 4 h at 37°C with human neutrophil elastase (HNE) at the 
concentrations indicated. At the end of the incubations, the reaction 
mixtures were subjected to 50S-PAGE and imlTlunoblotting with anti-a l-
proteinase inhibitor (A) or anti-aZ-macroglobulin (B). A ) LOlle S. 0. lZ5 JLg 
al-proteinase iJlhibitor standard. B) LOlle S, 0.5 JLg aZ-macroglobulin 
standard. Other deta ils arc in Moleria ls al/(I Methods. 
neutrophil elastase are responsible for fibrone ctin degradation in 
the chronic wound environnient. 
Relationship between Eiastase, a2-M, and at-PI Only 
wound fluid samples with total elastase levels exceeding the 
combined neutralization capacity of a2-M and a 1-PI should be able 
to degrade fib ro nectin ill " ilro. Wlul e (xl-PI was cleaved in these 
samples (i .e., Samples 2-1, 2-4, and 3-3) , some intact a2-M could 
still be detected . In wound fluid , this a2-M is like ly complexed 
with elastase, which cannot be detected using our current immu-
noblottin g m etho ds . That some a2-M in wound fluid was com-
plexed with e lastase can be inferred fi'om the difference between 
wound fluid elastase measured by the syntheti c peptide assay 
compared to th e ill "itra fibronectin degradatio n assay. That is, 
Samples 2-2, 2-3, and 3-1 contained elastase according to the 
peptide assay but little ill IIilYO fibronecti n-degrading activity. Pro-
teinases bound in the pocket of a2-M can still rea ct with small 
peptides, whereas th ey are inhibited from biuding to la rger protein 
substrates (Laurell and J eppsson , J 975; Petersen , 1993). 
Comparison of the proteinase inhibitor profiles of elastase-
treated m as tecto m y fluid with chronic ulcer wound fluid suggested 
that, at most, the elastase level of chronic wound fluid only slightly 
exceeded the proteinase inhibitor bufferin g ca pacity. As a result, the 
a2-M 85-kDa cleavage peptide in chro nic Lilce r wound fluid did 
not appear to be further degraded such as occurred w hen we 
doubl ed the elastase concentration used to treat mastectomy fluid. 
The observation that elastase did not appear to o verwhelm com-
pletely the proteinase inhibitors in chronic ulcer wound fluid is 
consistent with the idea that elasta se regulates its own expression in 
chronic inflammatory conditio ns through fee.dback inhibition 
m echan ism s. As the elastase concentration exceeds proteinase 
inhibito r buffering capacity, the enzyme can interfere with biolog-
ica l response mechanisms such as cell surface neutrophil receptors 
that are required for elastase release (Doring, 1994 ) . 
Gelatinase Activity Although gelatinases and other metaUopro-
teinases have been reported to degrade fibron ectin ill Il il,.o (Alex-
ander and Werb , 1991; Woessner, 1991; Birked al-Hansen el ai, 
1993), our studies suggest that fibron ectin is not a substrate for 
m etaUoproteinases in wound fluid . T hat is, EDTA blocked the 
ability of wound fluid to degrade type IV coll agen but had no effect 
on degradation of flbronectin. Also, most ill v itro studies (Murphy et 
THE J OU RN AL OF INV ESTIGAT1VE DEJ1..MATOLOGY 
ai , 1980; Okada el ai , 1989, 1992; D esl;vires el ai , 1993) have led to 
the belief that treatment of pro MMP-9 with elastase does not result 
in enzyme activation, whereas we fo und that in cubation of ma.s-
tectomy fluid with elastase resulted in cl eavage of MMP-9 and Its 
compl exes to processed enzymes form s (see also Vissers and 
Winterbourn, 1988) . T h ese results sugges t that there are important 
diffe rences between how m etalloproteinases (and probably other 
proteolytic enzymes) fun ction in complex biological fluids com-
pared with purified soluti ons. One possible explanation for such 
diffe rences is the presence of other, interacting proteinases. Anotl~er 
is that the bufFe ring effect of proteinase inhibi tors in biological. fh~lds 
influences not only proteinase activity, but also substrate speCifiCity. 
Patient and Ulcer Variability Previous studies on venous .' ta~is 
ulcer wound fluid showed considerable patient-to-patient variabil-
ity in fibronectin degradation (GI·jnnell el ai , 1992; Bulle~l el a~, 
1995) . Since the samples were obtained from individual patients, It 
was uncl ear whether the variability represen ted differences In the 
ul cers or in the times at which the ulcers were sampled. Our current 
fmdings using samples obtained at weekly in tervals over a month 
provide the first indication (based on a very limited se t of onl~ three 
patients) that the variability is with the ulcer, not with the tIIne at 
which the ulce r was sampled . That is, the overall patterns of 
fibronectin degradation were similar for all the wound fluid s;~mples 
from each individual patie nt, but very different from one patient to 
the next. 
The gelatinase profiles were also similar for each of the patients 
except in Samples 3 an d 4 from Patient 2 . In these samples, w.e 
o bserved a - 45-kDa gelatinase, which has been reported prevI-
ously to occur in some but not all chronic wound fluid samples 
(Wysocki cl aI, 1993; Bu llen el aI, 1995). Bull en el al (1995) 
suggested the - 45-kDa gelatinase might be a superactivated forl11. 
The appearance of this gelatinase concomitant with a Pseudomon.as 
infection raises the possibility that the - 45 kDa is a bactenaJ 
enzym e o r is produced in response to the infection. Data on more 
patients is c1earIy needed . . 
The different levels of fibron ectin degradation and protemase 
activity in different chronic ulcers emphasize the need to learn more 
about how these differences re late to ulcer pathology and treat-
ment. Although elevated proteinases and matrix degradation are 
potentially important fa ctors in chronic wounds (Fal anga . el nl, 
1994), it should not be overlooked that controlled expresslOl~ of 
proteinases in the wound envirol1.ment may contdbute to healll1g. 
Consistent with tlus idea, a variety of studies have demonstrated at 
least transient expression of proteinases following acute wounding 
(e.g., interstitial collagenase [Porras-Reyes el ai, 1991; Agren eI ai, 
1992; Saarialho-Kere cl aI, 1993, 1995; Stricklin cf aI, 1993 ; Inoue 
cl ai , 1995] , gelatinases [MMP-2 and MMP-9] [Chen el aI, 1992: 
Agren, 1994; Salo el aI , 1994; Young and Grinnell , 1994], plasmm-
ogen activator [Grondahl-Hansen el ai, 1988; Romer el aI, J 991; 
Schafe r ef ai, 1994], and elastase [Grinnell and Zhu, 1994; Hofer Ci 
al,19 95]). 
Finally, it should be noted tbat studies similar to ours have been 
carried out inde pendently by Rao el al (1 995). They also conclude 
that fibron ectin degradation in chronic ulcers can b e attributed to 
neutrophil elastase and that a 1-prote inase i!lhibitor (which they 
refer to as a 1-aJ1ti-trypsin) is degraded under these conditions. One 
important diffe rence between their o bservations and ours was the 
occurrence of extensive fibron ectin degradation in essentially all of 
the venous st.1sis ulcers they studied . T his difference may relate to 
the ir sampling procedure: they obtained wound fluid by mechanical 
expression frol11 wound dressings. 
T his resci/reh 'I'as SIIpporled by Naliollal illslilllles of Heald, Gralll CM21681. We 
lire i/lllel!fed 10 Drs. Will ialll S lIell a/lll Yillg-CIIIIII Lill for Illeir he/Iifid CO llllll elllS 
regardillg Ihe 1I la'II/Seripl, alld 10 Dr. Charles BaXlcr a/lll Ms. A llgciella Pm·ill .fo,r 
Ih eir ass isla lice Il'illl colleclillg 11'()J l/ld.flllid salllpies alld I'roJlidillg clillical oiJsc/"IIoliollS 
0 11 the patients 11/;,11 I/CII"S stasis "leers. 
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